Literature DB >> 7986773

Cannabis and acute psychosis.

P K McGuire1, P Jones, I Harvey, P Bebbington, B Toone, S Lewis, R M Murray.   

Abstract

The Present State Examination was used to assess the psychopathology of 23 psychotic patients who were cannabis positive on urinary screening, and 46 matched drug-free controls. Cases and controls were indistinguishable in terms of psychopathology, DSMIII diagnoses, onset of recent illness, the proportion of first admissions, ethnicity, and socio-economic class, differing only in their histories of substance use. These data suggest that psychosis which develops or recurs in the context of cannabis use does not have a characteristic psychopathology or mode of onset, and is not restricted to a particular ethnic or socio-demographic group. There is thus little evidence to support the validity of 'cannabis psychosis' as a diagnostic entity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7986773     DOI: 10.1016/0920-9964(94)90097-3

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  15 in total

Review 1.  Cannabis and psychosis.

Authors:  Louisa Degenhardt; Wayne Hall
Journal:  Curr Psychiatry Rep       Date:  2002-06       Impact factor: 5.285

Review 2.  Clinical implications and methodological challenges in the study of the neuropsychological correlates of cannabis, stimulant, and opioid abuse.

Authors:  Antonio Verdejo-García; Francisca López-Torrecillas; Carmen Orozco Giménez; Miguel Pérez-García
Journal:  Neuropsychol Rev       Date:  2004-03       Impact factor: 7.444

3.  Pre-illness cannabis use and the early course of nonaffective psychotic disorders: associations with premorbid functioning, the prodrome, and mode of onset of psychosis.

Authors:  Michael T Compton; Beth Broussard; Claire E Ramsay; Tarianna Stewart
Journal:  Schizophr Res       Date:  2010-10-30       Impact factor: 4.939

4.  Genetic predisposition to schizophrenia associated with increased use of cannabis.

Authors:  R A Power; K J H Verweij; M Zuhair; G W Montgomery; A K Henders; A C Heath; P A F Madden; S E Medland; N R Wray; N G Martin
Journal:  Mol Psychiatry       Date:  2014-06-24       Impact factor: 15.992

5.  (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population.

Authors:  Isabel Martínez-Gras; Janet Hoenicka; Guillermo Ponce; Roberto Rodríguez-Jiménez; Miguel Angel Jiménez-Arriero; Elena Pérez-Hernandez; Israel Ampuero; Jose Antonio Ramos-Atance; Tomas Palomo; Gabriel Rubio
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-06-20       Impact factor: 5.270

Review 6.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

7.  Involvement of opioid system in cognitive deficits induced by ∆⁹-tetrahydrocannabinol in rats.

Authors:  Nobuaki Egashira; Naomi Manome; Kenichi Mishima; Katsunori Iwasaki; Ryozo Oishi; Michihiro Fujiwara
Journal:  Psychopharmacology (Berl)       Date:  2011-08-20       Impact factor: 4.530

Review 8.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

9.  Role of vasopressin V1a receptor in ∆9-tetrahydrocannabinol-induced cataleptic immobilization in mice.

Authors:  Nobuaki Egashira; Emi Koushi; Takayuki Myose; Akito Tanoue; Kenichi Mishima; Ryota Tsuchihashi; Junei Kinjo; Hiroyuki Tanaka; Satoshi Morimoto; Katsunori Iwasaki
Journal:  Psychopharmacology (Berl)       Date:  2017-09-14       Impact factor: 4.530

Review 10.  Schizophrenia in black Caribbeans living in the UK: an exploration of underlying causes of the high incidence rate.

Authors:  Rebecca Pinto; Mark Ashworth; Roger Jones
Journal:  Br J Gen Pract       Date:  2008-06       Impact factor: 5.386

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.